OHSU

Graduate Studies Faculty

« Back to Search List



Tomasz M. Beer, M.D., F.A.C.P.

Grover C. Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology & Medical Oncology
Director, Prostate Cancer Research Program
Admin Unit: SOM-DOM Hematology & Medical Oncology
Phone: 503-494-4393
Fax: 503-494-6197
Office: Center for Health & Healing
Mail Code: CH14R
Programs:
Graduate Program in Clinical Nutrition
Research Interests:
prostate cancer, novel therapies, clinical trials and preclinical investigation
Preceptor Rotations
Academic Term Available Winter 2014 Yes Spring 2014 Yes Fall 2015 Yes Summer 2015 Yes Fall 2014 Yes
Faculty Mentorship
Dr. Beer is available as a mentor for 2013-2014. Dr. Beer is available as a mentor for 2014-2015.
Profile

Tomasz M. Beer, M.D., Grover C. Bagby Endowed Chair for Prostate Cancer Research,Professor of Medicine, Division of Hematology & Medical Oncology, and Deputy Director at the Oregon Health & Science University Knight Cancer Institute in Portland, Oregon.  Dr. Beer leads the Prostate Cancer Research Program within the OHSU Knight Cancer Institute, an NCI-designated Cancer Center.  He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991.  He then moved to Oregon Health & Science University.  At OHSU he completed his internship and residency in internal medicine and then completed his fellowship in Hematology and Medical Oncology.  Currently, he is a fellow of the American College of Physicians, as well as a member of several other professional societies, including American Society of Clinical Oncology, American Urologic Association, American Association for Cancer Research, and Southwest Oncology Group, where he has led a number of clinical trials.  Dr. Beer has authored and co-authored more than 250 articles and abstracts on prostate cancer largely with a focus on the development of novel therapies through clinical and translational investigation.  Dr. Beer’s major research interests include clinical trials, preclinical investigation, and risk factors in prostate cancer.